SCHEMBL24696708

SCHEMBL24696708

CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)N/N=C/c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.50
MAPT P10636 5/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
MEN1 O00255 5/20 0.48
ALDH1A1 P00352 2/20 0.48
POLB P06746 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
GAA P10253 1/20 0.48
PPARA Q07869 4/20 0.48
PPARG P37231 2/20 0.48
FABP2 P12104 1/20 0.48
SLC22A12 Q96S37 1/20 0.48
IKBKB O14920 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
GUSB P08236 1/20 0.45
AMY1A P0DUB6 1/20 0.44
USP2 O75604 1/20 0.44
ABCB11 O95342 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22221466 0.91 PPARA (0.58) KMT2AMAPTSMN1; SMN2MEN1ALDH1A1
SCHEMBL24696699 0.89 SMN1; SMN2 (0.56) KMT2AMAPTSMN1; SMN2MEN1ALDH1A1
SCHEMBL22221457 0.86 PPARA (0.56) KMT2AMAPTSMN1; SMN2MEN1ALDH1A1
SCHEMBL22221494 0.86 SMN1; SMN2 (0.53) KMT2AMAPTSMN1; SMN2MEN1ALDH1A1
SCHEMBL22221753 0.86 SMN1; SMN2 (0.53) KMT2AMAPTSMN1; SMN2MEN1ALDH1A1
SCHEMBL24696889 0.86 MEN1 (0.52) KMT2AMAPTSMN1; SMN2MEN1ALDH1A1
SCHEMBL22221754 0.85 SMN1; SMN2 (0.53) KMT2AMAPTSMN1; SMN2MEN1ALDH1A1
SCHEMBL22221501 0.85 PPARA (0.59) KMT2AMAPTSMN1; SMN2MEN1ALDH1A1
SCHEMBL22221759 0.84 MAPT (0.54) KMT2AMAPTSMN1; SMN2MEN1ALDH1A1
SCHEMBL24697351 0.83 LMNA (0.53) KMT2AMAPTSMN1; SMN2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220304957-A1 ANTI-CANCER COMPOSITIONS AND METHODS OF USE UNIV LOUISIANA STATE (US) 2022-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220304957-A1 ANTI-CANCER COMPOSITIONS AND METHODS OF USE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, MCL1 KMT2A 2060/4885MAPT 3049/4885SMN1; SMN2 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.